High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients
about
Association of the breast cancer antiestrogen resistance protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistanceRelationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer linesOverexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways.Phosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states.Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.EgoNet: identification of human disease ego-network modulesA prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index.BikDDA, a mutant of Bik with longer half-life expression protein, can be a novel therapeutic gene for triple-negative breast cancer.Unraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approachAdvances in small-molecule drug discovery for triple-negative breast cancer.Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer.TMEFF2 modulates the AKT and ERK signaling pathwaysReduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor ResistanceTrends of triple negative breast cancer research (2007-2015): A bibliometric study.Emerging targeted agents in metastatic breast cancer.Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma.Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).Down regulation of RhoC by microRNA-138 results in de-activation of FAK, Src and Erk1/2 signaling pathway in head and neck squamous cell carcinoma.c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.Targetting PED/PEA-15 for diabetes treatment.Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer.Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways.Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells.Metastasis suppressors: functional pathways.Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer
P2860
Q28308160-13A74855-DE95-4E84-9FA2-FB89F7149994Q28542662-9677C0DB-8BF0-4FA8-A3AB-56503CF684A0Q33275573-ACA48826-80CC-4417-82D5-D00849254441Q33913833-1C7A8671-9818-461E-8CFC-C41D85663D40Q34024181-BCDD5D86-5392-4E3D-97C5-BBF11D9C12CFQ34455301-66AA63EF-A886-48B4-B41F-C742009796C1Q34525552-37BA444C-4694-463E-8C1A-7D4E4BFA46CFQ35067947-2B69DA1E-CAA6-4564-A087-8A9232F02523Q35122880-7937F6E7-46B4-4228-A53B-8C91D461E8F2Q35312645-AB59C3EE-0FB0-4CEA-A647-0F0A4411ED82Q35818491-84A348FD-5E16-40F8-BE55-34BB1FB25BDFQ35861891-935097CA-4DCC-4889-BB7E-AB00194D71C2Q37059535-F284DA66-CD88-4DED-AD74-49389565A3C9Q37380418-81D37FED-7BBF-4868-861A-7D2498B39B37Q37433105-95B97530-C801-45E5-A5E4-DA850486F0BFQ38086421-3DD97D2E-5FFF-4667-8D79-ECC6CDD7C188Q38399495-42CE6E6E-6B28-4156-9FB2-68F6E4DBF55CQ38949880-AD421F26-45B7-47A4-A56C-1D705BD52A09Q39021212-7DCA4D9F-B115-465B-A7D0-B9ACB875B12BQ39110390-324A7DD8-371F-4938-88AA-903FD90DD503Q39232367-383AC70C-686C-41AF-B112-C4308F584C8BQ42657804-6A5BCEF9-3300-4D8E-9D9C-03A02D0307BFQ45412843-265B7A45-DF84-4402-96E9-FEADDC1C609BQ47381221-9B9AD1D2-604E-4F9F-853B-2B59A6EE80EEQ47716769-96BC3931-B420-4C21-8794-B84843C6E0AEQ51023485-BE5C275D-4FE0-467B-B900-2C0BD7458052Q53478339-E26EB230-6F4A-44E4-A239-6275E0BC4C58Q57105411-BDD42FE1-0B82-4654-92F7-7E2C392072F7
P2860
High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
High ERK protein expression le ...... egative breast cancer patients
@ast
High ERK protein expression le ...... egative breast cancer patients
@en
type
label
High ERK protein expression le ...... egative breast cancer patients
@ast
High ERK protein expression le ...... egative breast cancer patients
@en
prefLabel
High ERK protein expression le ...... egative breast cancer patients
@ast
High ERK protein expression le ...... egative breast cancer patients
@en
P2093
P2860
P1433
P1476
High ERK protein expression le ...... egative breast cancer patients
@en
P2093
Ana M Gonzalez-Angulo
Chandra Bartholomeusz
Gabriel N Hortobágyi
Jaime Ferrer-Lozano
Naoki Hayashi
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0377
P50
P577
2012-05-14T00:00:00Z